Yeonsoo Baik
Overview
Explore the profile of Yeonsoo Baik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Musinguzi A, Kasidi J, Kadota J, Welishe F, Nakitende A, Akello L, et al.
PLOS Glob Public Health
. 2024 Oct;
4(10):e0003347.
PMID: 39446746
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify...
2.
Musinguzi A, Kasidi J, Kadota J, Welishe F, Nakitende A, Akello L, et al.
medRxiv
. 2024 Sep;
PMID: 39314926
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify...
3.
Baik Y, Bien-Gund C, Bisson G, Gross R, Fishman J
Public Health Pract (Oxf)
. 2024 Mar;
7:100483.
PMID: 38449769
Objectives: In the United States, a federal emergency program has made SARS-CoV-2 self-test kits available at no cost. It is unclear how widely free tests are preferred. We conducted a...
4.
Semitala F, Kadota J, Musinguzi A, Welishe F, Nakitende A, Akello L, et al.
PLoS Med
. 2024 Feb;
21(2):e1004356.
PMID: 38377166
Background: Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people...
5.
Maenetje P, Baik Y, Schramm D, Vangu M, Wallis R, Mlotshwa M, et al.
J Infect Dis
. 2023 Jun;
229(3):824-832.
PMID: 37386883
Background: Identification of proinflammatory factors responding to Mycobacterium tuberculosis is important to reduce long-term sequelae of pulmonary tuberculosis (TB). Methods: We examined the association between plasma biomarkers, the fraction of...
6.
Baik Y, Maenetje P, Schramm D, Tiemessen C, Ncube I, Churchyard G, et al.
BMC Pulm Med
. 2023 Feb;
23(1):53.
PMID: 36737697
Background: Patients with tuberculosis (TB) and HIV often present with impairments in lung function and exercise capacity after treatment. We evaluated clinical and immunologic variables associated with a minimum clinically...
7.
Fishman J, Bien-Gund C, Bisson G, Baik Y
Am J Prev Med
. 2022 Nov;
64(3):438-440.
PMID: 36411144
No abstract available.
8.
Baik Y, Cilloni L, Kendall E, Dowdy D, Arinaminpathy N
Epidemics
. 2022 Sep;
41:100631.
PMID: 36174427
Background: Diagnostic testing plays a critical role in the global COVID-19 response. Polymerase chain reaction (PCR) tests are highly accurate, but in resource-limited settings, limited capacity has led to testing...
9.
Jo Y, Baik Y, Shrestha S, Pennington J, Gomes I, Reja M, et al.
Epidemiol Infect
. 2022 May;
149:e209.
PMID: 35506926
We developed a novel method to align two data sources (TB notifications and the Demographic Health Survey, DHS) captured at different geographic scales. We used this method to identify sociodemographic...
10.
Baik Y, Hanrahan C, Mmolawa L, Nonyane B, Albaugh N, Lebina L, et al.
Clin Infect Dis
. 2021 Jul;
74(6):957-964.
PMID: 34212181
Background: Providing incentives to screen close contacts for tuberculosis (TB) is an alternative to household-based contact investigation. We aimed to characterize patients and contexts where this incentive-based strategy might be...